Increased Number of Shares and Votes in Medivir

STOCKHOLM--(BUSINESS WIRE)-- The number of shares and the number of votes in Medivir (STO:MVIRB) have changed as a result of the rights issue carried out by the company as well as the exercise of employee stock options.

Today, the last trading day of the month, there are in total 26,222,662 shares and 32,162,662 votes in Medivir.

Based on its world class expertise in protease and polymerase inhibition technology, Medivir develops drugs with primary focus on infectious diseases. Its objective is to become a sustainable and profitable specialty pharmaceutical company with a strong research base.

Medivir’s first pharmaceutical product - for the topical treatment of cold sores - has recently been approved by the US FDA (trademark "Xerese™") and in Europe (trademark "Xerclear™"). The product will be commercialized through partners outside the Nordic region, where Medivir intends to market and sell the product.

For more information on Medivir, please see the company website:

This information was brought to you by Cision


Rein Piir, CFO & VP Investor Relations
Office phone +46 8 54683123
Cell phone +46 708 537 292.

KEYWORDS:   Europe  Sweden

INDUSTRY KEYWORDS:   Health  Biotechnology  Pharmaceutical  Research  Science


Suggested Articles

In the first half of 2020, the regenerative medicine sector raised $10.7 billion, more than the total it raised in 2019.

Creating new, successful central nervous system drugs is tough, and Lundbeck knows this better than most after canning an internal CNS effort.

After seeing later stage trials come through in obesity, Novo Nordisk is canning two projects that were aiming to help reduce patients’ weight.